Chimpanzee Biomedical Research Program Limited Competition (U42)

黑猩猩生物医学研究计划有限公司竞赛（U42）

• 批准号: 8199817
• 负责人: m. babette Fontenot
• 金额: $ 185.9万
• 依托单位: UNIVERSITY OF LOUISIANA AT LAFAYETTE
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-01 至 2014-09-15
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8199817
• 关键词: Age; Animal Model; Behavioral; Behavioral Research; Biological Availability; Biomedical Research; Breeding; Chronic Hepatitis B; Communities; Conceptions; Continuing Education; Databases; Development; Diabetes Mellitus; Disease; Drug Compounding; Drug Kinetics; Evaluation; Food; Future; General Population; Genetic; Goals; Guidelines; HCV Vaccine; HIV; Health; Health Policy; Health Status; Healthcare; Hepatitis; Hepatitis A Virus; Hepatitis B Vaccines; Hepatitis C; Hepatitis C Vaccine; Hepatitis C virus; Human; Human Subject Research; Immunotherapy; International; Kidney Diseases; Long-Term Care; Louisiana; Medicine; Methods; Modeling; Monoclonal Antibodies; Monoclonal Antibody Therapy; Neuropeptides; Pan Genus; Pan troglodytes; Pharmaceutical Preparations; Pharmacodynamics; Phenotype; Play; Population; Principal Investigator; Process; Proteins; Research; Research Personnel; Research Support; Resources; Respiratory syncytial virus; Risk; Role; Safety; Schools; Science; Social Interaction; Strategic Planning; Testing; United States; United States National Institutes of Health; Universities; Vaccines; Work; base; data sharing; demographics; high school; meetings; monoamine; novel; outreach; programs; prophylactic; public education; teacher; web page

DESCRIPTION (provided by applicant): The biomedical and behavioral research community has long recognized the importance of chimpanzees (Pan troglodytes) as an animal model. In 1986 the National Institutes of Health created the Chimpanzee Breeding and Research Program (CBRP) to insure that a chimpanzee population in the United States was available for use in human health research. The University of Louisiana at Lafayette has been active in this endeavor since its conception. Chimpanzees continue to be essential models in the development of vaccines for hepatitis B virus, hepatitis C virus, hepatitis A virus, respiratory syncytial virus, and human immunodeficiency virus and play a critical role in the evaluation of the pharmacodynamics, pharmacokinetics, bioavailability, safety, and efficacy of novel drug compounds, proteins and monoclonal antibodies. Specific aims of the application include the following: 1) To maintain CBRP chimpanzees in a setting which promotes species appropriate social interactions and, to establish and implement guidelines for managing access to research chimpanzees based on age and health status. 2) To conduct a longitudinal resource relevant research focused on: 1) characterization of naturally occurring disease processes and 2) determination of the relationship between specific behavioral phenotypes and levels of central monoamine metabolites and neuropeptides. 3)To collaborate and share data freely with the chimpanzee database grantees, investigators whose efforts would be supported by access to UL Lafayette's information and the ChiMP Coordinator, and to work with the ChiMP Advisory Panel in developing long term plans for research use, demographics, genetics, and long-term care. 4)To support national and international efforts to share biomedical research resources consistent with the National Institutes of Health's policy on Sharing of Model Organisms for Biomedical Research, and to enhance the development of and access to chimpanzee animal models critical to understanding human health need consistent with NCRR's 2004-2008 Strategic Plan. PUBLIC HEALTH RELEVANCE (provided by applicant): The CBRP resource is critical to meeting global human health care challenges. Accessing a chimpanzee model is essential in selective cases for reducing risk to human research subjects. The chimpanzee is the only model available to meet the needs of advancing a vaccine for hepatitis C and for the development of future monoclonal antibodies therapies.

描述(由申请人提供)：生物医学和行为研究界早就认识到黑猩猩(泛轮虫)作为动物模型的重要性。1986年，美国国立卫生研究院创建了黑猩猩繁育和研究计划(CBRP)，以确保美国的黑猩猩种群可用于人类健康研究。路易斯安那大学拉斐特分校自成立以来一直积极参与这项工作。黑猩猩仍然是发展乙肝病毒、丙型肝炎病毒、甲型肝炎病毒、呼吸道合胞病毒和人类免疫缺陷病毒疫苗的重要模型，并在评价新药化合物、蛋白质和单抗的药效学、药代动力学、生物利用度、安全性和有效性方面发挥着关键作用。该应用程序的具体目标包括： 1)使CBRP黑猩猩保持在促进物种适当社会互动的环境中，并根据年龄和健康状况制定和实施管理接触研究黑猩猩的指导方针。 2)开展与资源相关的纵向研究，重点是：1)自然发生疾病过程的特征；2)特定行为表型与中枢单胺代谢物和神经肽水平之间的关系。 3)与黑猩猩数据库受赠者、研究人员(他们的工作将得到UL Lafayette信息的访问)和黑猩猩协调员自由协作和共享数据，并与黑猩猩顾问小组合作，制定研究用途、人口统计学、遗传学和长期护理的长期计划。 4)根据国家卫生研究院关于共享生物医学研究模式生物的政策，支持国家和国际努力共享生物医学研究资源，并根据NCRR的2004-2008年战略计划，加强对了解人类健康需求至关重要的黑猩猩动物模型的开发和获取。 公共卫生相关性(由申请者提供)：CBRP资源对于应对全球人类卫生保健挑战至关重要。访问黑猩猩模型在特定情况下对于降低人类研究对象的风险至关重要。黑猩猩是唯一可用的模型，以满足发展丙型肝炎疫苗和发展未来的单抗疗法的需要。